Search

Your search keyword '"Brun JG"' showing total 165 results

Search Constraints

Start Over You searched for: Author "Brun JG" Remove constraint Author: "Brun JG"
165 results on '"Brun JG"'

Search Results

1. AB0160 Interferon-Γ-inducible kynurenines inflammation pathway: the missing link between disease activity and symptoms in sjÖgren's syndrome

2. SAT0270 Ultrasonography of major salivary glands in juvenile sjÖgren's syndrome – preliminary findings in a multi-center study

3. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)

4. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). in combination wiIh methotrexate

6. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome

14. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome.

18. Calprotectin (S100A8/A9), S100A12, and EDTA-resistant S100A12 complexes (ERAC) in primary Sjögren's syndrome.

21. Variants in the DDX6-CXCR5 autoimmune disease risk locus influence the regulatory network in immune cells and salivary gland.

22. Author Correction: Genome-wide association study identifies Sjögren's risk loci with functional implications in immune and glandular cells.

23. Author Correction: Genome-wide association study identifies Sjögren's risk loci with functional implications in immune and glandular cells.

24. Aberrant signaling of immune cells in Sjögren's syndrome patient subgroups upon interferon stimulation.

25. Genome-wide association study identifies Sjögren's risk loci with functional implications in immune and glandular cells.

26. Impaired activation of STAT5 upon IL-2 stimulation in Tregs and elevated sIL-2R in Sjögren's syndrome.

27. Genetic variants at the RTP4/MASP1 locus are associated with fatigue in Scandinavian patients with primary Sjögren's syndrome.

28. Inflammatory Stratification in Primary Sjögren's Syndrome Reveals Novel Immune Cell Alterations in Patients' Minor Salivary Glands.

29. Lipid, fatty acid, carnitine- and choline derivative profiles in rheumatoid arthritis outpatients with different degrees of periodontal inflammation.

30. Temporomandibular joint pain and associated magnetic resonance findings: a retrospective study with a control group.

31. Acinar adipose tissue infiltration in salivary gland biopsy is associated with kynurenines-Interferon-γ pathway inflammation biomarkers.

32. Juvenile Sjögren's Syndrome: Clinical Characteristics With Focus on Salivary Gland Ultrasonography.

33. Assessment of major salivary gland ultrasonography in Sjögren's syndrome. A comparison between bedside and post-examination evaluations.

34. Single Cell Based Phosphorylation Profiling Identifies Alterations in Toll-Like Receptor 7 and 9 Signaling in Patients With Primary Sjögren's Syndrome.

35. Marine ω-3, vitamin D levels, disease outcome and periodontal status in rheumatoid arthritis outpatients.

36. Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health.

37. T follicular-like helper cells in the peripheral blood of patients with primary Sjögren's syndrome.

38. Aberrant cell signalling in PBMCs upon IFN-α stimulation in primary Sjögren's syndrome patients associates with type I interferon signature.

39. Patients with Primary Sjögren's Syndrome Have Alterations in Absolute Quantities of Specific Peripheral Leucocyte Populations.

40. Long-term follow-up in primary Sjögren's syndrome reveals differences in clinical presentation between female and male patients.

41. Identification of a Sjögren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons.

42. Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium.

43. Serum calprotectin is a biomarker of carotid atherosclerosis in patients with primary Sjögren's syndrome.

44. Sjögren's syndrome patients with ectopic germinal centers present with a distinct salivary proteome.

45. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).

46. Atherosclerosis in Sjögren's syndrome: evidence, possible mechanisms and knowledge gaps.

47. TLR-7 and -9 Stimulation of Peripheral Blood B Cells Indicate Altered TLR Signalling in Primary Sjögren's Syndrome Patients by Increased Secretion of Cytokines.

48. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI).

49. High fidelity between saliva proteomics and the biologic state of salivary glands defines biomarker signatures for primary Sjögren's syndrome.

50. Expression of Toll-like receptor -7 and -9 in B cell subsets from patients with primary Sjögren's syndrome.

Catalog

Books, media, physical & digital resources